Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and...
Alternative Titles
Full title
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5adb93bde37e447fb7b9fd11a0d65568
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5adb93bde37e447fb7b9fd11a0d65568
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-020-00977-0
